For more than 20 years, Laurie Zollinger had mentally prepared herself for the possibility.
Still, when the news hit, she sat in her living room, stared out the front window, and thought, "Oh, my God, what if this goes bad?"
Zollinger's grandmother was diagnosed with breast cancer in her early 50s, and Zollinger knew her genetics put her at higher risk for the disease.
"I always just felt like I was going to hear those words someday," she says of a breast cancer diagnosis, "and that day happened July 1, 2020."
After a routine mammogram—delayed a few months due to the COVID-19 pandemic—Zollinger was diagnosed with stage 2A triple-negative breast cancer. In the year following her diagnosis, Zollinger and her wife, Andrea Brenner, logged more than 10,000 miles between their home in Sterling, Illinois, and the University of Iowa Holden Comprehensive Cancer Center for what Zollinger describes as a "higher level of care."
Zollinger knew to expect side effects from the cancer treatments such as nausea, vomiting, and hair loss. But one side effect she was unfamiliar with until her own experience was "chemo brain"—the lay term for a mental fog associated with cancer and its treatment that can cause difficulties in thinking, focus, and memory.
Doctors don't know exactly what causes chemo brain. It may be a side effect of some chemotherapy drugs that pass through the blood-brain barrier or the result of physical and psychological stress on the body related to cancer and its treatment.
According to recent studies cited by Iowa researchers of women with breast cancer, up to 60 percent of participants reported neurocognitive symptoms after undergoing chemotherapy, with the effects lasting anywhere from six months to more than a decade. In Zollinger's case, she started noticing symptoms of chemo brain after her second chemotherapy treatment, struggling with short-term memory loss, word retrieval, and slow reaction times. "I wasn't good for driving," she says about handing the car keys over to Brenner to make the two-hour drive to Iowa City for appointments.
Patients like Zollinger have shared concerns with their physicians about cognitive impairments during and following cancer treatment, but little research had been done on chemo brain to be able to help—and to objectively tie their symptoms to what was happening inside the brain. Over the past few years, a multidisciplinary team of Iowa researchers have collaborated to understand the understudied phenomenon and find possible treatments for patients through two new clinical trials. Both studies peer into the inner workings of the brain through cutting-edge neuroimaging, and one of the trials takes a novel approach to treatment with transcranial magnetic stimulation (TMS), a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain.
"It's important because it's really shining a light on treating a whole person and not just treating a disease," says Dr. Sneha Phadke (16F, 18CER, 20MPH), a UI medical oncologist and clinical assistant professor of internal medicine involved in the collaboration. "We want someone to live as long as possible, but we also want that to be a high-quality life."
For many of the UI researchers who study chemo brain, the drive to help patients is deeply personal. Kanchna Ramchandran (11PhD, 14CER), an associate research scientist in the UI Department of Internal Medicine at the Roy J. and Lucille A. Carver College of Medicine, remembers the helplessness and heartbreak she felt after losing her mother in India to gynecological cancer while she was a graduate student at Iowa halfway across the world.
"As she went through her treatment process, I watched this bright, sharp lady go through these periods of confusion and fog, and it was very unlike her," says Ramchandran. "This research is my way of saying thank you to my family for taking care of her, but also for me to do something for anybody who's going through a cancer diagnosis. It's a way of giving back."
Ramchandran chose Iowa for its historic leadership in neuroscience and gained expertise under mentors such as Daniel Tranel (81MA, 82PhD), the F. Wendell Miller Professor of Psychological and Brain Sciences and Neurology who helped create one of the largest brain lesion registries in the world, and Dr. Nancy Andreasen (70MD), the Andrew H. Woods Chair of Psychiatry who is an internationally renowned expert on schizophrenia and a pioneer in neuroimaging. "I received full intellectual, academic, and scientific freedom to pick any questions that came my way," says Ramchandran, "and then they would help me curate that into a good study design and help find funding support to actually execute that."
Ramchandran says she's "always been happiest at the intersection of research and practice," so in honor of her mother, she helped assemble an expert team of UI faculty, staff, and students to discover potential causes of and treatments for chemo brain. The group has specialists in neuroscience, oncology, psychiatry, radiology, and statistics. It also includes undergraduate research assistants who receive academic research credit through the UI Center for Research by Undergraduates to collect and score data, process scans, and help with data analysis. Among these students is Kesten Anderson, a UI senior who has worked with Ramchandran since high school and became fascinated by neuroscience after her father had a massive stroke. Now with six years of research under her belt, Anderson says, "The skills I have acquired in Dr. Ramchandran's lab have provided me with a firm foundation in research that I will be able to use in the years to come."
Since 2018, the Iowa Fraternal Order of Eagles' Art Ehrmann Cancer Fund has provided annual support for the UI team's research. The funding helped launch a pilot study to identify brain-based biomarkers that might be associated with chemo brain and a second study to explore an innovative treatment. In 2019, the UI team also secured a $20,000 Institutional Research Grant from the American Cancer Society through the Holden Comprehensive Cancer Center to support the second chemo brain study.
Zollinger felt strangely empowered as she watched clumps of her hair fall to the ground. Shaving her head outside her home in September 2020, Zollinger says she relished the opportunity to control the inevitable hair loss caused by chemotherapy—and she also liked her bold new look. Two weeks after her first chemotherapy treatment, she posted photos on Facebook, sharing her story in hopes that it would motivate others to get their annual mammograms. Shortly after, two friends told her the post inspired them to schedule their first mammograms.
From sharing her journey with others to making gratitude lists on the way to doctor appointments, Zollinger saw her cancer diagnosis as an opportunity to practice positive thinking. So, when Dr. Mark Karwal (84MD, 94F), a UI clinical professor of internal medicine and an oncologist and hematologist at UI Hospitals & Clinics, approached her about participating in Iowa's pilot study to better understand chemo brain, Zollinger eagerly volunteered. "I felt like if they could learn something from me to help the next woman going through it, it could give me peace to know something good was going to come out of the struggle," she says.
Ramchandran and Phadke call clinical trial participants "the real heroes" of medicine. During a particularly difficult moment in their lives, these volunteers devote their time and energy to a study, and although they may never benefit personally from the results of the research, their participation can spark medical breakthroughs that could help future patients. "Patient advocates have really changed the course of how we as physicians and investigators see this disorder, so if it wasn't for the dedication of those people, there probably wouldn't be funding for studies like this today," says Phadke. "I think we owe a lot of gratitude for those people who didn't give up, who were told that nothing's wrong with them."
Before Zollinger received her first chemotherapy treatment, Ramchandran and Anderson led her into a room at the UI Magnetic Resonance Research Facility at the Pappajohn Biomedical Discovery Building, where they conducted a series of neuropsychological tests and did a brain scan. Open to breast cancer and lymphoma patients, the study evaluates patients' problem-solving and thinking skills. Patients may play a memory game, take a basic math quiz, or rearrange cards with pictures on them into a logical series of events. The puzzles provide researchers with a baseline from which to compare the patients' cognitive performance during and after cancer treatment.
In addition to the puzzles, Zollinger filled out a weekly online questionnaire that helped track her mood, sleep, pain, cognitive functioning, and levels of anxiety and depression throughout the treatment process.
Undoubtedly the most revealing part of the study came when Zollinger laid still in a cold, white scanner for an hour as the technician took photos of her brain activity. Vince Magnotta (94MS, 97PhD), director of the UI Magnetic Resonance Research Facility and a professor of radiology, biomedical engineering, and psychiatry, helped design this portion of the study using the 7Tesla scanner. The state-of-the-art brain imaging tool for researchers not only captures detailed pictures of the regions of the brain associated with executive functioning but can also measure concentrations and ratios of various brain chemicals in those areas. Zollinger says she's done MRI scans in the past, but none like this one where the researchers could examine the brain at a molecular level.
"I felt like if they could learn something from me to help the next woman. going through [breast cancer], it could give me peace to know something good was going to come out of the struggle." —Laurie Zollinger on joining a UI clinical trial
About six months after her first visit to the lab, Zollinger returned following her final chemotherapy treatment to retest and do a second scan for comparison. With the effects of chemo brain setting in, Zollinger says she noticed the same tests felt more challenging the second time. Words didn't come as quickly as they used to.
Although researchers are still in the process of collecting data from the pilot study, Ramchandran says they have noticed patterns within individuals that suggest their overall turmoil from cancer and chemotherapy may be at least temporarily affecting their cognitive functioning. Some of these individuals show significant changes in their concentration of metabolites in the brain regions of interest following chemotherapy. While it's too early to draw any implications or definitive scientific conclusions, Ramchandran says she is cautiously optimistic these leads may hold hope in providing physicians a proper method of assessing and diagnosing chemo-induced cognitive deficits in the future.
For more information or to join one of the clinical trials, email firstname.lastname@example.org or call 319-356-0535. You can also follow these links:
Since Zollinger completed her treatment, Iowa researchers have started a second small clinical trial that Ramchandran describes as entering "uncharted territory." The trial is open to nearly all adult cancer patients—except for brain cancer patients—who have completed chemotherapy and are still experiencing the symptoms of chemo brain.
In addition to the testing and scanning that Zollinger experienced, participants in this clinical trial receive TMS, which has recently been approved by the FDA to treat major depressive disorder, obsessive-compulsive disorder, migraine headache, and nicotine addiction. To administer the treatment, researchers use computer-assisted technology to place a coil strategically on the patient's head. The coil sends short bursts of electromagnetic stimulation to the brain that excite neural activity in the areas of the prefrontal cortex involved with executive function.
TMS treatments typically are time-intensive, requiring patients to come in five days a week for four to six weeks for the 40-minute therapy. But with the help of Dr. Nicholas Trapp (19MS), a UI assistant professor of psychiatry and director of Interventional Psychiatry Services, Iowa researchers are applying accelerated intermittent theta burst stimulation in this clinical trial. The Iowa scientists cluster their patients' treatments together to increase the speed at which it can modulate brain activity and function. The unique approach cuts patient treatment time down to one week.
Ramchandran says that a couple of other national studies use neuromodulation—the alteration of nerve activity—to help treat chemo brain in cancer patients, but she believes this Iowa clinical trial is the only one offering an accelerated form of treatment.
With both clinical trials in their early stages, it may take some time before Iowa researchers see whether their contributions to the study of chemo brain will lead to real-life applications for cancer patients. If the initial data looks promising, researchers can secure larger grants to conduct more widescale studies with the goal of seeing if their methods are an effective and safe way to diagnose and treat chemo brain.
Although there's not yet an approved diagnostic tool or cure for chemo brain, Zollinger says it's meaningful for her to know the UI Health Care team is listening and responding to patients' needs and concerns with its research. "It's kind of like depression," she says about chemo brain. "I think sometimes people look at that and say, 'That's not real.' But it is. People need to understand, and if this can help people understand that it's physically a real, chemical thing that is happening in the brain, that's awesome, because that takes away the stigma of it."
Zollinger's cancer treatment at Iowa included a lumpectomy, two different types of chemotherapy that lasted five months, and a month of radiation. Receiving chemotherapy amid the COVID-19 pandemic, she went through one of the most difficult periods of her life without being able to see her parents in Florida or hug her sons. "As a caretaker, you feel helpless," says Brenner about the lowest points of Zollinger's cancer journey, "because there is nothing you can do to make them feel better."
Fortunately, Zollinger had the care and expertise of her Holden Comprehensive Cancer Center team, which included her medical oncologist, Dr. Karwal; her surgeon, Dr. Sonia Sugg; and her radiation oncologist, Dr. Kristin Plichta (18R). Zollinger also expressed gratitude for the rest of the UI Hospitals & Clinics staff—from the receptionists at check-in and the counselors who brought psychological support, to the nurses who gave her hugs through their protective gear and the radiology technicians who rang a bell to mark the end of her treatment. "I was really impressed with the team here," she says. "I felt like everybody knew what was going on, and they worked together."
Zollinger is now cancer-free. Although she says her mind is not quite where it was before chemotherapy, she has seen a gradual improvement, has resumed driving, and has never stopped working as an audiologist. She's appreciated how her experience with cancer has helped her family grow closer and develop a healthier lifestyle.
As she looks back at her cancer journey, Zollinger also feels grateful for the opportunity to participate in a UI clinical trial that might make the road easier for future cancer patients with chemo brain. "That was very important to me, because I felt it gave me purpose, and it was empowering that I could choose that part," she says. "I never thought I would say this, but so many more positives than negatives have come from this. It's been life-changing in a good way."
UI Holden Comprehensive Cancer Center recently received its fourth renewal from the National Cancer Institute as a comprehensive cancer center. Learn more about Iowa's only comprehensive cancer center, or give to Holden.
For more information or to join one of the clinical trials, email email@example.com or call 319-356-0535. You can also follow these links: